Paid Hepatitis C Clinical Trials
Hepatitis C clinical trials recruiting. Access new shortened treatment regimens. Studies for treatment-naive and treatment-experienced patients with HCV.
Compensation
$1,500 - $3,500
Duration
12-24 weeks
Phase
Phase II/III
FDA Regulated
IRB Approved
GCP Certified
Who May Qualify
- Age 18-75 years
- Chronic hepatitis C infection (HCV RNA detectable)
- Known HCV genotype
- Liver disease staging (FibroScan or biopsy) within past 12 months
- No evidence of hepatocellular carcinoma
- Compensated liver function if cirrhosis present
Who May Not Qualify
- Decompensated cirrhosis (Child-Pugh B or C)
- Hepatitis B co-infection (unless controlled)
- Prior liver transplant (unless study-specific)
- HIV co-infection (unless specifically included)
- Current or recent hepatocellular carcinoma
Frequently Asked Questions
What hepatitis C treatments are being studied?
+
Current studies focus on shortened treatment durations, simplified regimens, and treatments for difficult-to-cure populations including those with prior treatment failure or decompensated cirrhosis.
How long is treatment in these studies?
+
Many current studies are testing 8-week or even shorter courses compared to previous 12-week standards. Some studies involve single-dose or weekly treatments rather than daily pills.
What is the cure rate in clinical trials?
+
Modern direct-acting antivirals achieve sustained virologic response (cure) rates of 95-99% in most patient populations. Studies track viral load throughout treatment and for 12 weeks after.
Can I participate if I have cirrhosis?
+
Yes, studies are available for patients with compensated cirrhosis. Some trials specifically enroll patients with advanced liver disease, though decompensated cirrhosis is typically excluded.